Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eton Pharmaceuticals (ETON) Depreciation and Depletion (2019 - 2025)

Eton Pharmaceuticals (ETON) has disclosed Depreciation and Depletion for 7 consecutive years, with $17000.0 as the latest value for Q4 2025.

  • Quarterly Depreciation and Depletion fell 55.26% to $17000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $41000.0 through Dec 2025, down 46.05% year-over-year, with the annual reading at $41000.0 for FY2025, 18.0% down from the prior year.
  • Depreciation and Depletion hit $17000.0 in Q4 2025 for Eton Pharmaceuticals, up from $8000.0 in the prior quarter.
  • In the past five years, Depreciation and Depletion ranged from a high of $84000.0 in Q1 2021 to a low of $4000.0 in Q2 2025.
  • Historically, Depreciation and Depletion has averaged $19100.0 across 5 years, with a median of $13500.0 in 2022.
  • Biggest five-year swings in Depreciation and Depletion: crashed 75.0% in 2022 and later surged 216.67% in 2024.
  • Year by year, Depreciation and Depletion stood at $23000.0 in 2021, then plummeted by 43.48% to $13000.0 in 2022, then fell by 7.69% to $12000.0 in 2023, then soared by 216.67% to $38000.0 in 2024, then plummeted by 55.26% to $17000.0 in 2025.
  • Business Quant data shows Depreciation and Depletion for ETON at $17000.0 in Q4 2025, $8000.0 in Q3 2025, and $4000.0 in Q2 2025.